Jun 07,2021

Voluntis receives FDA 510(k) clearance for a new version of Insulia supporting an expanded range of basal insulins

Voluntis a leader in digital therapeutics, today announced that it has received the FDA 510(k) clearance for a new version of Insulia supporting an additional basal insulin product, expanding the scope of insulins covered by the solution. Voluntis’ flagship diabetes digital therapeutic, Insulia, helps people with type 2 diabetes with dose titration. It is indicated for patients with type 2 diabetes initiating or uncontrolled on basal insulin, treated with a wide range of basal insulin analogues, including all approved insulin glargines.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 02,2021

ABBOTT'S FREESTYLE® LIBRE 2 IOS APP CLEARED IN U.S., PROVIDING A SEAMLESS DIGITAL EXPERIENCE TO SIMPLIFY DIABETES MANAGEMENT

Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Providing breakthrough technology that is accessible and affordable4, the FreeStyle Libre portfolio is the number one continuous glucose monitoring (CGM) system worldwide5 and most prescribed in the U.S.6, changing the lives of nearly 3.5 million people across more than 50 countries including 1 million users in the U.S.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 22,2021

Welldoc Receives Ninth 510(k) for Award-Winning Diabetes Platform, BlueStar®

Welldoc, a digital health leader revolutionizing chronic care, today announced the receipt of its ninth 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes platform, BlueStar®. The new clearance expands insulin dosing support to most types of insulin, including Bolus and Premixed Insulin titration for type 2 diabetes.

REGULATORY FDA

#dtx

View Analyst & Ambassador Comments
Go to original news
Jun 28,2022

FDA Approved Device in 2022 | TaiDoc

Based on the customer’s demands, and market trend that Taidoc have submitted cholesterol parameter to FDA and now gratefully to announce that it has passed FDA Class II with 510(k) in June 2022.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 03,2021

POGO Automatic One-Step™ Blood Glucose Monitor Now Available for People with Diabetes in the United States

Intuity Medical, Inc., a commercial-stage medical technology and digital health company focused on making life with diabetes easier, announced today the availability of the POGO Automatic® Blood Glucose Monitoring System in the U.S. The product is the first and only FDA-cleared blood glucose monitor whose 10-test cartridge technology makes a glucose test possible with only the press of a button and without needing to carry separate test strips and lancets.

REGULATORY FDA

#bgm

View Analyst & Ambassador Comments
Go to original news
Mar 02,2020

Tandem Diabetes Care Announces FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ™ technology as an interoperable automated glycemic controller (iAGC). This is the second system to receive iAGC designation by the FDA, following the Company’s clearance of the t:slim X2™ insulin pump with Control-IQ™ technology in December 2019.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Mar 30,2020

Jana Care receives US FDA clearance for Aina HbA1c Monitoring System 2

Jana Care today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Aina HbA1c Monitoring System 2, an automated glycated hemoglobin (HbA1c) test system. Glycated hemoglobin is primarily used to determine the three-month average blood sugar level and can be used to monitor long term glycemic control of persons previously diagnosed with diabetes. The system is among the first smartphone-based blood testing devices approved by the US FDA.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
May 06,2020

DarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines

DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters including Dario's smartphone-connected metering device may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

REGULATORY FDA

#bgm

View Analyst & Ambassador Comments
Go to original news
May 22,2020

Medtronic Guardian™ Connect Continuous Glucose Monitoring (CGM) System for Diabetes Now Compatible with Android Devices

Medtronic (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval for the Android™ version of its Guardian™ Connect continuous glucose monitoring (CGM) system.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 03,2020

Welldoc Receives FDA Clearance for Long-Acting Insulin Support for Award-Winning Digital Health Solution BlueStar®

Welldoc, revolutionizing digital health with the first FDA-cleared Software as a Medical Device (SaMD) for diabetes, announced today that U.S. Food and Drug Administration (FDA) has cleared an additional feature for the digital health product BlueStar Rx which supports individuals using long-acting insulin. The Insulin Adjustment Program (IAP), supports the process of basal insulin titration by health care providers for adults with type 2 diabetes.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Subscribe to FDA